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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine is Black Cohosh effective 
for reducing anxiety/depression symptoms in postmenopausal women? 
 
DESIGN: Review of three English language primary randomized controlled studies published 
from 2005-2009. 
 
DATA SOURCES: Randomized, double blind, placebo-controlled trials comparing Black 
Cohosh to placebo or hormonal therapies were found using PubMed and Cochrane databases.  
 
OUTCOMES MEASURED: Each of the three trials assessed the efficacy and clinical 
improvement in anxiety symptoms with the use of Black Cohosh. Studies utilized to measure 
change in anxiety symptoms included Harrison Anxiety Rating (HAM), Symptom Rating Test 
(SRT), and Kupperman Test.  
 
RESULTS:  Two double-blind randomized controlled trials were included in this review. Results 
from the Amsterdam et al study indicates that Black Cohosh use had little vasomotor or 
anxiolytic activity, however the sample size in this study was small. The second study by Nappi 
et al concluded that after the use of Black Cohosh reduced anxiety/depression as well as 
vasomotor symptoms in postmenopausal women to the same degree as hormone therapy. The 
third study by Vermes et al showed a reduction in anxiety/ depression symptoms. The 
Kupperman index scores also decreased over the duration of the study. All three trials 
demonstrated that Black Cohosh does contribute reduction in anxiety/depression in menopausal 
women.  
 
CONCLUSIONS: All of the RCT and Clinical Trial demonstrate that Black Cohosh use is 
effective at reducing anxiety/depression. Black Cohosh seems to be the same effectiveness as 
Hormonal therapy available for anxiety/depression in postmenopausal women.  
 
KEY WORDS: Black Cohosh (Remifemin, Cimicifuga racemosa) , anxiety, depression 
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INTRODUCTION 
 
Menopause is defined as occurring 12 months after your last menstrual period and marks 
the end of menstrual cycles. Menopause can happen in your 40s or 50s. Postmenopausal is after 
one has undergone menopause. There are many symptoms associated with menopause, such as 
anxiety and depression that can make life challenging.1 Anxiety can be described as a sense of 
foreboding, such as feeling as if something is wrong.  Women can experience palpitations, 
shortness of breath, trembling, lightheadedness, as well as other symptoms due to anxiety.2 
Additionally, women approaching menopause are at increased risk for depression, which may be 
from hormonal changes.2 This paper evaluates two randomized, double blind control trials and 
one clinical trial comparing the efficacy of Black Cohosh to placebo/ hormone replacement 
therapy.  
Anxiety and Depression in postmenopausal women is relevant to the Physician Assistant 
profession due to its high rates of prevalence today. It is estimated that 65% - 85% of women 
experience vasomotor symptoms related to menopause, and 30% seek medical attention for these 
symptoms.2 Although vasomotor symptoms are most pronounced during the initial years of 
menopause, nearly 64% of women will continued to experience vasomotor symptoms up to 5 
years after menopause, and 26% of women will have symptoms lasting up to 10 years.1 
Currently Black Cohosh is highly affordable since it is available without a prescription. The cost 
of a one-month supply of the product ranges from $16 to $60 depending upon the dosage.1 
Hormone replacement therapy (HRT) has been the mainstay for treatment. 
Benzodiazepine have become treatment of choice for anxiety symptoms, despite the presence of 
BZ-induced dependence and antidepressant-induce sexual side effects, weight gain, and 
withdrawal. These side effects are why women are seeking alternative medicine, Black Cohosh, 
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remedies for their climacteric symptoms.2 
Menopause can cause a number of physical changes that may cause anxiety themselves. 
It is well known that menopause appears to increase risk for panic attacks but the cause and 
effect is not exactly clear. Menopausal anxiety can be hormone mediated, hormone exacerbated, 
or simply menopausal related. 1 
 Usual methods used to treat menopausal anxiety include Hormone Replacement 
Therapy, such as Medroxyprogesterone.  Additionally, antidepressants are used in combination 
with Hormonal Replacement Therapy, such as, fluoxetine, paroxetine, and venlafaxine, can be 
used to control anxiety and other menopausal symptoms. Among the pharmacological treatment, 
benzodiazepines, Xanax, are the drug of choice for anxiety in postmenopausal women. Also, 
other Complementary Alternative Medications, dong quai, black cohosh, St. Johns wort, and 
ginkgo biloba, are becoming popular due to the side effects of pharmacologic treatment.3 
The above treatments are effective options for postmenopausal women suffering from 
anxiety and efficacy of the treatment varies from patient to patient. Women with comorbidities 
or history of past breast or uterine cancer, blood clots, liver disease, and stroke are not good 
candidates for Hormone Replacement Therapy. Black Cohosh may be a natural anxiolytic 
alterative to these regimens in reducing anxiety in postmenopausal women and will be discussed 
further in this review.3 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Does Black 
Cohosh improve anxiety/ depression symptoms in women who are postmenopausal?” 
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METHODS 
The three studies utilized in this review include two randomized control trials and 
one clinical trial, which met the following criteria: The population consisted of 
postmenopausal women with symptoms of anxiety. The intervention used was Black 
Cohosh 64mg, 40mb/day. The treatment group receiving Black Cohosh versus the 
experimental group receiving either visually matched placebo or HRT.3,4 Outcomes 
measured include the efficacy of Black Cohosh for the treatment of Anxiety or 
depression incidences in postmenopausal women.  
Key word used to locate the literature consisted of Black Cohosh (Black Cohosh 
(Remifemin, Cimicifuga racemosa) , anxiety, and depression. All articles were published 
in English and published in peer-reviewed journals.  The articles were searched via 
PubMed and were selected based on their relevance to my clinical question and if they 
included patient oriented outcomes (POEMS). Inclusion criteria consisted of randomized 
controlled trials and clinical trials with postmenopausal women. Exclusion criteria consist 
of previous hormone therapy or contraindications to hormonal therapy. Statistics that 
were reported and utilized are relative risk reduction (RRR), absolute risk reduction 
(ARR), numbers needed to treat (NNT), Standard Deviation, p-values, baseline tests, 
ANOVA.3,4,5 
 
 
Demographics and characteristics of the studies utilized for review are displayed in Table 1. 
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Study Type # Pts Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Amsterdam 
(2009) 
Randomized 
Control Trial 
34 >40 -Women who were either 
postmenopausal for more 
than 12 months or peri-
menopausal [with 
amenorrhea lasting 2 to 
11 months in the 
proceeding year] were 
included  
-Women with prior 
hysterectomy an 
uncertain menopausal 
status had a serum follicle 
stimulating hormone 
level greater than or equal 
to 40 mIU/l. 
other CAM remedies, 
oral estrogen, estrogen 
cream, or phyto-estrogen 
preparation was not 
permitted. Peri-
menopausal women 
employed a medically 
proven, nonhormonal 
form of contraception and 
had a negative pregnancy 
test. 
 
Axis I diagnosis of 
Major Depressive 
Disorder, Bipolar 
Disorder, Panic 
Disorder Phobic 
Disorder, Obsessive- 
compulsive 
Disorder, Post-
traumatic Stress 
Disorder, Acute 
Stress Disorder, 
Substance- induced 
Anxiety Disorder, 
Schizophrenia, 
Dementia, or 
Substance Abuse or 
Dependence 
Disorder within the 
preceding 3 months. 
 
6 -64 mg Black cohosh 
BID for first 2 weeks 
-4 capsules daily of  
128 mg Black cohosh 
by study week 4 with 
less than or equal to 
50% reduction in total 
baseline HAM-A score. 
 
Nappi 
(2005) 
Randomized 
Control Trial 
64 45-
55 
-Spontaneous menopausal 
status of at least 6 months 
with follicle- stimulating 
hormone [FSH] level > 
30 mUI/l 
-Presence of hot flushes 
[atleast fiver per day] and 
endometrial thickness <5 
mm. 
 
Previous hormone 
therapy or 
contraindications to 
hormonal treatments 
 
4 40 mb/day of 
isopropanolic aqueous 
CR extract for 3 
months 
 
Vermes 
(2005) 
Clinical Trial 2016 45-
65 
Kupperman index (20), 
refusal or 
contraindication for 
estrogen therapy 
Pts on HRT 140 Remifemin tablets BID 
PO x 12 weeks 
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OUTCOMES MEASURED 
 All outcomes measured in the trials were based on patient oriented evidence that assessed 
the efficacy and clinical improvement in anxiety as well as other menopausal symptoms in 
women. The Amsterdam et al study primarily used HAM-A scores between the two groups to 
measure outcomes. Secondary outcomes used in Amsterdam et al study included Beck Anxiety 
Inventory (BAI) and Green Climacteric Scale (GCS).3 Nappi et al measured the change in 
anxiety and depression using the Symptoms Rating Test (SRT).4 Lastly, Vermes et al also used 
the Kupperman index, which utilized the severity of the symptoms. This was evaluated at the 
start of the study and throughout the study.5  
RESULTS 
 The results for the Amsterdam et al study was that 34 patients were originally enrolled in 
the study and 6 patients were screen failures who withdrew consent to participate. The patients 
were randomized to either black cohosh or placebo. 75% of patients completed all study visits 
and were used for the results. The final results of the study showed that the HAM-A score at 
study endpoint had no significant difference. There was a greater reduction in total GCS scores 
favoring placebo (-4.45 (95% CI= (-8.59, 3.12; p= 0.035)).3 
 
Table 2 Characteristics of Black Cohosh and Placebo groups 
 
Black Cohosh 
(n=15) Placebo (n=13) p-value** 
Caucasian (%) 71.43 61.54 0.78 
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Age (years) * † 56.7 (6.53)/50-76 50.8 (3.22)/47-57 0.0064 
Age at onset of GAD (years) 
* 43.6 (8.6)/19-53 44.9 (11.4)/10-55 0.36 
Episode Duration (months) * 60.7 (91.6)/5-180 27.9 (29.4)/4-108 0.11 
Illness Duration (years) * † 13.1 (12.1)/1-42 6.7 (10.7)/1-39 0.032 
Number prior GAD Episodes 
* 6.3 (20.5)/0-80 1.3 (2.9)/0-10 0.30 
Baseline HAM-A Score * 16.9 (3.8)/10-22 15.9 (3.5)/9-22 0.39 
Baseline BAI Score * 11.8 (6.7)/3-26 14.1 (8.6)/5-36 0.66 
Baseline PGWB Score * 112.4 (19.5)/84-142 115.2 (24.1)/76-158 0.75 
*Mean (SD)/range;  **Pearson x2 test (binary variables) or Wilcoxon Rank sum test 
(continuous variables) 
 
Table 3: Estimated difference in Overall change for treatment groups using regression model  
Outcome Est. Change Diff in Groups (60β) 
95% CI for Change 
Diff 
p 
value 
HAM-A −1.58 −4.53 to 1.37 0.294 
BAI −1.07 −6.14 to 1.96 0.578 
GCS total −4.45 −8.59 to −3.12 0.035 
GCS 
psychological −2.68 −5.51 to .15 0.063 
GCS anxiety −1.52 −3.44 to .4 0.121 
GCS depression −1.17 −2.76 to .42 0.148 
PGWB 11.06 −3.63 to 25.75 0.140 
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Table 4: Estmated values in overall change for treatment groups using regression model (2) 
Outcome Est. Change Diff Cohosh Est. Change diff Placebo Effect Size p value 
HAM-A -2.56 -4.90 0.72 0.294 
BAI -1.17 -4.46 0.34 0.578 
GCS Total 0.56 -3.94 0.85 0.035 
GCS 
anxiety 
0.0084 
 
-1.93 0.55 0.121 
GCS 
depression 
-0.19 -0.98 0.54 0.148 
 
Table five for the Nappi et study shows the baseline characteristics of the women treated with 
Black Cohosh (CR) and low dose TTSE.  
 
 
Table 5 [CR (n = 32)] [TTSE2 (n = 32)] p Value 
Age (years) 50.5+/- 2.1 50.9 +/- 1.8 0.37 
Menopause (months) 9.0 +/- 2.9 9.1 +/- 3.0 0.87 
Body Mass Index 22.9 +/- 2.2 22+/- 2.1 0.40 
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As shown in Figure 1  Black Cohosh (CR) was significantly effective in reducing both anxiety 
(p< 0.001) and depression (p< 0.001) measured by SRT following three months of treatment 
 
Figure 14 
The results for the Vermes et al study showed that the Kupperman index scores decreased 
through the course of the study. The decline was most extreme during the first 4 weeks of 
treatment. The total mean score decreased at a constant rate of from one evaluation period to the 
next, decreasing first at 8.12, then by 5.56, and finally by 3.96 points.5  
 
 
Table 6. Changes in the Kupperman Menopause Index in the Course of Treatment 
Symptom Week 0   Week 4  Week 8  Week12  
Anxiety 1.77 3.53 1.29 2.57 0.96 1.92 0.77 1.53 
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Mean/SD 0.021 0.042 0.019 0.038 0.017 0.033 0.016 0.032 
 
Discussion 
 Many menopausal and postmenopausal women are searching for CAM remedies to 
relieve their menopause related symptoms. CAM therapies are becoming more popular due to 
their decreased concern about drug toxicity and side effects, cultural attitudes, and the stigma of 
having a psychological disorder.3,5 The primary solution for the symptoms of menopause is 
HRT, however, many patients are afraid of the risk of breast cancer and deep vein thrombosis 
associated with it.5 Nappi et al. compared the efficacy of Black Cohosh compared to HRT in 
reducing menopausal symptoms and found a significant reduction in menopause-related 
psychological symptoms. Nappi et al. study was limited by the absence of a placebo group.4 
With the Amsterdam et al. study there are several caveats that need to be considered in their 
findings. There was a lower than expected subject enrollment and small sample size with limited 
ability to detect difference between treatment condition, which provides no clinical 
meaningfulness.3 Additionally, in the Vermes et al. study the Kupperman index was used and a 
mean 17.64 point decrease was observed during the twelve weeks of treatment. This finding is 
suggestive that the extract of C racemosa (Remifemin) reduces the intensity of menopausal 
symptoms effectively. Additionally, drug tolerability was considered excellent by the patients 
themselves and their physicians. The limitations for Vermes et al. study include that the study 
was not a placebo-controlled trial. Second, he findings were based on an assessment of changes 
in subjective symptoms rather than objective symptoms. 5 
Conclusion 
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 According to the Amsterdam et al. study Black Cohosh appears to be effective in 
reducing the vasomotor symptoms of menopause and minimal activity for anxiolytic symptoms. 
However, Amsterdam et al. study noted that the sample size was extremely small, and the choice 
of Black Cohosh preparation dosage had limited their ability to identify the clinical 
meaningfulness of Black Cohosh over placebo.3 Nappi et al. study concludes that Black Cohosh 
(40mg/day) can be considered a consistent and safe option to counteract specific symptoms in 
postmenopausal women.4 In conclusion Vermes et al. study states that Remifemin may 
effectively reduce the severity of symptoms of menopause and Remifemin shows promise as an 
effective therapeutic choice for menopausal complaints. 5 
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